SA author Austrolib provides a run-through of cancer vaccines from the "underwhelming to the...
SA author Austrolib provides a run-through of cancer vaccines from the "underwhelming to the exciting." The latter includes OncoVEX from Amgen (AMGN), which would be a buy if it weren't "skirting its all-time highs of $89 a share." Even more interesting are DCVax-L (brain) and DCVax-Direct (inoperable tumors) from Northwest Biotherapeutics (NWBO.OB). The problem is that Northwest has little cash and lots of debt notes.
From other sites
at Investopedia (Apr 9, 2015)
at Investopedia (Apr 6, 2015)
at Nasdaq.com (Mar 26, 2015)
at Zacks.com (Mar 26, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs